Ä¢¹½ÊÓƵAPP

About Omega Epigenomic Controllersâ„¢ and Epigenomic Programmingâ„¢

Omega Therapeutics is developing novel engineered and modular therapeutics, called Omega Epigenomic Controllers, that are designed to target with high specificity and downregulate or upregulate the level of expression of any of the 25,000+ human genes, individually or collectively, with controlled durability, to treat and potentially cure disease. The foundation of Omega's platform lies within the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and conserved structures called Insulated Genomic Domains (IGDs). Omega's technology exploits the topology and functionality of these IGDs as druggable targets to activate the genome's innate ability to treat and cure disease. Omega's medicines are being developed to be dosed only as frequently as therapeutically necessary by intervening at the pre-transcriptional level and function without altering the native human genetic code or nucleic acid sequences.

About Omega Therapeutics

Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Ä¢¹½ÊÓƵAPP following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, and multigenic diseases including inflammatory and cardiometabolic conditions. For more information, visit , or follow Omega on and .